CG
BMRN icon

Cutler Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cutler Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$9K Sell
2,200
-6,000
-73% -$537K ﹤0.01% 1305
2023
Q4 		$70K Buy
+8,200
New +$725K 0.01% 1235
2022
Q4 		– Sell
-5,000
Closed -$14K – 4420
2022
Q3 		$14K Buy
+5,000
New +$445K ﹤0.01% 2859
2022
Q2 		– Sell
-25,800
Closed -$5K – 4983
2022
Q1 		$5K Sell
25,800
-67,400
-72% -$5.64M ﹤0.01% 4095
2021
Q4 		$149K Buy
+93,200
New +$7.69M 0.01% 1551
2021
Q3 		– Sell
-700
Closed -$1K – 5716
2021
Q2 		$1K Buy
+700
New +$55.5K ﹤0.01% 5208
2021
Q1 		– Sell
-13,900
Closed -$33K – 5639
2020
Q4 		$33K Buy
13,900
+13,800
+13,800% +$1.09M ﹤0.01% 2296
2020
Q3 		$1K Sell
100
-6,500
-98% -$658K ﹤0.01% 4258
2020
Q2 		$126K Buy
+6,600
New +$656K 0.01% 1154
2019
Q2 		– Sell
-3,000
Closed -$2K – 4230
2019
Q1 		$2K Sell
3,000
-17,500
-85% -$1.62M ﹤0.01% 3334
2018
Q4 		$9K Buy
20,500
+16,800
+454% +$1.6M ﹤0.01% 2575
2018
Q3 		$19K Sell
3,700
-9,900
-73% -$988K ﹤0.01% 2260
2018
Q2 		$21K Sell
13,600
-2,500
-16% -$219K ﹤0.01% 2154
2018
Q1 		$16K Buy
16,100
+600
+4% +$51.5K ﹤0.01% 2426
2017
Q4 		$59K Buy
15,500
+3,900
+34% +$339K ﹤0.01% 1736
2017
Q3 		$65K Sell
11,600
-37,700
-76% -$3.33M ﹤0.01% 2002
2017
Q2 		$139K Sell
49,300
-24,500
-33% -$2.23M 0.01% 1579
2017
Q1 		$103K Buy
73,800
+52,400
+245% +$4.66M ﹤0.01% 1708
2016
Q4 		$52K Sell
21,400
-28,200
-57% -$2.43M ﹤0.01% 2496
2016
Q3 		$84K Buy
49,600
+12,500
+34% +$1.18M ﹤0.01% 1949
2016
Q2 		$57K Buy
37,100
+13,700
+59% +$1.16M ﹤0.01% 2217
2016
Q1 		$90K Sell
23,400
-32,500
-58% -$2.64M 0.01% 1707
2015
Q4 		$252K Buy
+55,900
New +$5.84M 0.01% 1002

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group's BMRN Position: Q3 2023 in Review

Cutler Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 800 shares — an estimated $69K sold.

Cutler Group first reported a position in BMRN in Q4 2015 and held it in 27 quarters. The position peaked at $2.76M in Q3 2016. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Cutler Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 800 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $69K.
  • Cutler Group first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 27 quarters.
  • Cutler Group's BioMarin Pharmaceuticals position peaked at $2.76M in Q3 2016.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.